Reliable detection of amyloid pathology is essential for Alzheimer's disease (AD) diagnosis and treatment. We directly compared routine ELISA assays and the automated Lumipulse platform against quantitative amyloid PET in a real-world memory clinic cohort. In 153 participants, flutemetamol amyloid PET and CSF biomarkers were assessed across platforms. Concordance with PET and predictors of discordance were evaluated. PET visual reads and Centiloids showed near-perfect agreement (AUC = 0.99). The p-tau181/Aβ42 ratio achieved the highest concordance with PET (OPA 87% ELISA, 92% Lumipulse), while the Lumipulse Aβ42/40 ratio reached 93%. About 6% of participants showed consistent discordance between CSF and PET, associated with APOE ε4 and mixed or non-AD pathologies. Automated CSF assays align strongly with amyloid PET and support biomarker standardization. Persistent discrepancies between CSF and PET likely reflect underlying biological heterogeneity such as mixed or non-AD pathologies and APOE ε4 carriage.

Department of Natural Sciences Faculty of Biomedical Engineering Czech Technical University Prague Prague Czech Republic

Department of Neurology 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

PET Centre Na Homolce Hospital Prague Czech Republic

Zobrazit více v PubMed

Jack Jr., C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. PubMed PMC

Jack, C. R. et al. NIA-AA research framework: Toward a biological definition of Alzheimer’s disease. PubMed DOI PMC

Cummings, J. et al. Lecanemab: Appropriate use recommendations. PubMed DOI PMC

Donanemab: Appropriate use recommendations. PubMed PMC

Salloway, S. et al. Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer’s disease. PubMed DOI PMC

Seo, S. W. et al. Regional correlations between [11C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort. PubMed DOI PMC

Clark, C. M. et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. PubMed DOI

Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. PubMed DOI PMC

Hanseeuw, B. J. et al. PET staging of amyloidosis using striatum. PubMed DOI PMC

Klunk, W. E. et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. PubMed DOI PMC

Battle, M. R. et al. Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods. PubMed DOI PMC

La Joie, R. et al. Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer’s disease neuropathology. PubMed DOI PMC

Hanseeuw, B. J., Malotaux, V., Dricot, L., Quenon, L., Sznajer, Y, Cerman, J. et al. Defining a Centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [18F] flutemetamol amyloid PET study. PubMed PMC

van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., et al. Lecanemab in early Alzheimer’s disease. PubMed

Farrar, G., Weber, C. J., Rabinovici, G. D. Expert opinion on Centiloid thresholds suitable for initiating anti-amyloid therapy. Summary of discussion at the 2024 spring Alzheimer’s Association Research Roundtable. PubMed PMC

Vos, S. J. B. et al. Variability of CSF Alzheimer’s disease biomarkers: implications for clinical practice. PubMed DOI PMC

Mattsson, N. et al. The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers. PubMed DOI PMC

Verwey, N. A., van der Flier, W. M., Blennow, K., Clark, C., Sokolow, S., De Deyn, P. P., et al. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer’s disease. PubMed

Park, S. A. et al. Comparative analysis of Elecsys and ELISA for differentiating amyloid-PET status in a Korean memory clinic based on cerebrospinal fluid biomarkers. PubMed DOI

Orellana, A. et al. Establishing in-house cutoffs of CSF Alzheimer’s disease biomarkers for the AT(N) stratification of the Alzheimer Center Barcelona Cohort. PubMed DOI PMC

Sauvée, M. et al. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer’s disease pathophysiological process in routine practice. PubMed DOI

Fagan, A. M. et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. PubMed DOI

Schindler, S. E. et al. Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. PubMed DOI PMC

Landau, S. M. et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid. PubMed DOI PMC

Reimand, J., de Wilde, A., Teunissen, C. E., Zwan, M., Windhorst, A. D., Boellaard, R., et al. PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases. PubMed PMC

Mattsson, N. et al. CSF biomarker variability in the Alzheimer’s Association quality control program. PubMed DOI PMC

Zwan, M. D. et al. Use of amyloid-PET to determine cutpoints for CSF markers. PubMed DOI PMC

Karlsson, L. et al. Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases. PubMed DOI PMC

Mravinacová, S. et al. Addressing inter individual variability in CSF levels of brain derived proteins across neurodegenerative diseases. PubMed DOI PMC

Mastenbroek, S. E. et al. Continuous β-amyloid CSF/PET imbalance model to capture alzheimer disease heterogeneity. PubMed DOI PMC

Woodward, M., MacKenzie, I. R. A., Hsiung, G. Y. R., Jacova, C. & Feldman, H. Multiple brain pathologies in dementia are common. DOI

Wang, B. W. et al. Multiple pathologies are common in Alzheimer patients in clinical trials. PubMed DOI

Fortea, J. et al. APOE4 homozygosity represents a distinct genetic form of Alzheimer’s disease. PubMed DOI

Glodzik-Sobanska, L. et al. The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer’s disease. PubMed DOI PMC

Greenberg, B. D. et al. CSF Alzheimer disease biomarkers. PubMed DOI PMC

Monge-Argilés, J. A. et al. Influence of APOE genotype on Alzheimer’s disease CSF biomarkers in a Spanish population. PubMed DOI PMC

Guillén, N. et al. Agreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter study. PubMed DOI PMC

Moon, S. et al. Alzheimer’s cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans. PubMed DOI PMC

Willemse, E. A. J. et al. Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status. PubMed PMC

Hansson, O. et al. CSF biomarkers of Alzheimer’s disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. PubMed DOI PMC

Campbell, M. R. et al. P-tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status. PubMed DOI PMC

Alcolea, D. et al. Agreement of amyloid PET and CSF biomarkers for Alzheimer’s disease on Lumipulse. PubMed DOI PMC

Cerman, J. et al. Cerebrospinal fluid ratio of phosphorylated tau protein and beta amyloid predicts amyloid pet positivity. DOI

Sheardova, K., Vyhnálek, M., Nedelska, Z., Laczo, J., Andel, R., Marciniak, R., et al. Czech Brain Aging Study (CBAS): Prospective multicentre cohort study on risk and protective factors for dementia in the Czech Republic. PubMed PMC

Petersen, R. C. Mild cognitive impairment. PubMed PMC

Albert, M. S. et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. PubMed DOI PMC

McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. PubMed DOI PMC

Jessen, F. et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. PubMed DOI PMC

Rascovsky, K. et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. PubMed DOI PMC

Gorno-Tempini, M. L. et al. Classification of primary progressive aphasia and its variants. PubMed DOI PMC

Hoglinger, G. U. et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. PubMed DOI PMC

McKeith, I. G. et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. PubMed DOI PMC

Regier, D. A., Kuhl, E. A. & Kupfer, D. J. The DSM-5: Classification and criteria changes. PubMed PMC

Belohlavek, O., Jaruskova, M., Skopalova, M., Szarazova, G. & Simonova, K. Improved beta-amyloid PET reproducibility using two-phase acquisition and grey matter delineation. PubMed DOI PMC

Vanderstichele, H. et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer’s disease diagnosis: a consensus paper from the Alzheimer’s Biomarkers Standardization Initiative. PubMed DOI

Gobom, J. et al. Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. PubMed DOI

Amadoru, S. et al. Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease. PubMed DOI PMC

Blennow, K. & Zetterberg, H. Biomarkers for Alzheimer’s disease: current status and prospects for the future. PubMed DOI

Collij, L. E. et al. Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent. PubMed DOI PMC

Royse, S. K. et al. Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach. PubMed DOI PMC

Rafii, M. S. et al. The AHEAD 3–45 study: Design of a prevention trial for Alzheimer’s disease. PubMed DOI PMC

Jovalekic, A. et al. Experiences from clinical research and routine use of florbetaben amyloid PET—A decade of post-authorization insights. PubMed DOI PMC

Rothenberg, K. G. et al. Cerebral amyloid angiopathy in patients with cognitive impairment: cerebrospinal fluid biomarkers. PubMed DOI PMC

Sembill, J. A. et al. Cerebrospinal fluid biomarkers for cerebral amyloid angiopathy. PubMed DOI PMC

Margraf, N. G., Jensen-Kondering, U., Weiler, C., Leypoldt, F., Maetzler, W., Philippen, S., et al. Cerebrospinal fluid biomarkers in cerebral amyloid angiopathy: New data and quantitative meta-analysis. PubMed PMC

Theodorou, A. et al. CSF and plasma biomarkers in cerebral amyloid angiopathy: A single-center study and a systematic review/meta-analysis. PubMed DOI PMC

Giagkou, N., Kapsali, I., Brinia, M. E. & Constantinides, V. C. Cerebrospinal fluid total and phosphorylated tau protein in behavioral variant frontotemporal dementia, progressive supranuclear palsy, corticobasal syndrome and non-fluent agrammatic primary progressive aphasia: a systematic review and meta-analysis. PubMed DOI PMC

Ossenkoppele, R. et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. PubMed DOI PMC

Kolinger, G. D. et al. Quantification of baseline amyloid PET in individuals with subjective cognitive decline can identify risk of amyloid accumulation and cognitive worsening: the FACEHBI study. PubMed DOI PMC

de Wilde, A. et al. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences. PubMed DOI PMC

Serrano-Pozo, A., Das, S. & Hyman, B. T. APOE and Alzheimer’s disease: advances in genetics, pathophysiology, and therapeutic approaches. PubMed DOI PMC